| Year |
Citation |
Score |
| 2017 |
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, ... ... Legos J, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The New England Journal of Medicine. PMID 28891408 DOI: 10.1056/Nejmoa1708539 |
0.318 |
|
| 2017 |
Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, ... ... Legos JJ, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer (Oxford, England : 1990). 82: 45-55. PMID 28648698 DOI: 10.1016/J.Ejca.2017.05.033 |
0.306 |
|
| 2015 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, ... ... Legos JJ, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 386: 444-51. PMID 26037941 DOI: 10.1016/S0140-6736(15)60898-4 |
0.3 |
|
| 2014 |
Hauschild A, Grobb J, Demidov L, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank C, Miller W, Martin-Algarra S, Karaszewska B, Mauch C, Chiarion Sileni V, Aktan G, Haney P, ... ... Legos J, et al. 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv378. PMID 28171162 DOI: 10.1093/Annonc/Mdu344.8 |
0.301 |
|
| 2014 |
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Sun P, ... ... Legos J, et al. Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.39 |
0.312 |
|
| 2008 |
Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Experimental Neurology. 212: 53-62. PMID 18462720 DOI: 10.1016/J.Expneurol.2008.03.011 |
0.393 |
|
| 2003 |
McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E. Caspase 3 activation is essential for neuroprotection in preconditioning. Proceedings of the National Academy of Sciences of the United States of America. 100: 715-20. PMID 12522260 DOI: 10.1073/Pnas.0232966100 |
0.314 |
|
| 2002 |
Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. European Journal of Pharmacology. 447: 37-42. PMID 12106800 DOI: 10.1016/S0014-2999(02)01890-3 |
0.324 |
|
| 2002 |
Legos JJ, Tuma RF, Barone FC. Pharmacological interventions for stroke: failures and future. Expert Opinion On Investigational Drugs. 11: 603-14. PMID 11996643 DOI: 10.1517/13543784.11.5.603 |
0.589 |
|
| 2002 |
Weaver M, Leshley K, Sands H, Gritman KR, Legos JJ, Tuma RF. LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia. Microvascular Research. 63: 327-34. PMID 11969309 DOI: 10.1006/Mvre.2002.2405 |
0.603 |
|
| 2002 |
Legos JJ, Gopez JJ, Young WF. Non-surgical management of spinal cord injury. Expert Opinion On Investigational Drugs. 11: 469-82. PMID 11922856 DOI: 10.1517/13543784.11.4.469 |
0.379 |
|
| 2002 |
Legos JJ, Mangoni AA, Read SJ, Campbell CA, Irving EA, Roberts J, Barone FC, Parsons AA. Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat. Journal of Neuroscience Methods. 113: 159-66. PMID 11772437 DOI: 10.1016/S0165-0270(01)00488-5 |
0.336 |
|
| 2001 |
Legos JJ, Gritman KR, Tuma RF, Young WF. Coadministration of methylprednisolone with hypertonic saline solution improves overall neurological function and survival rates in a chronic model of spinal cord injury. Neurosurgery. 49: 1427-33. PMID 11846943 DOI: 10.1097/00006123-200112000-00022 |
0.584 |
|
| 2001 |
Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O' Brien S, Clark S, Brawner M, Bates S, Gloger I, Legos JJ, Barone FC. Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 21: 755-78. PMID 11435788 DOI: 10.1097/00004647-200107000-00001 |
0.307 |
|
| 2001 |
Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, et al. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Medicinal Research Reviews. 21: 129-45. PMID 11223862 DOI: 10.1002/1098-1128(200103)21:2<129::Aid-Med1003>3.0.Co;2-H |
0.408 |
|
| 2001 |
Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Research. 892: 70-7. PMID 11172750 DOI: 10.1016/S0006-8993(00)03228-5 |
0.616 |
|
| 2001 |
Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, Erhardt JA, Nelson AH, Ohlstein EH, Hunter AJ, Ward K, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. The Journal of Pharmacology and Experimental Therapeutics. 296: 312-21. PMID 11160612 |
0.308 |
|
| 2001 |
Sumas ME, Legos JJ, Nathan D, Lamperti AA, Tuma RF, Young WF. Tonicity of resuscitative fluids influences outcome after spinal cord injury. Neurosurgery. 48: 167-72; discussion 1. PMID 11152342 DOI: 10.1097/00006123-200101000-00029 |
0.579 |
|
| 2001 |
Legos JJ, Lee D, Erhardt JA. Caspase inhibitors as neuroprotective agents Emerging Drugs. 6: 81-94. DOI: 10.1517/14728214.6.1.81 |
0.377 |
|
| 2000 |
Legos JJ, Whitmore RG, Erhardt JA, Parsons AA, Tuma RF, Barone FC. Quantitative changes in interleukin proteins following focal stroke in the rat. Neuroscience Letters. 282: 189-92. PMID 10717423 DOI: 10.1016/S0304-3940(00)00907-1 |
0.546 |
|
| 2000 |
Legos JJ, Erhardt JA, Haimbach RE, Boland PM, Chandra S, Lenhard SC, Irving EA, Hunter J, Sarkar SK, Ohlstein EH, Barone FC, Parsons AA. Extracellular Signal Regulating Kinase Phosphorylation and Diffusion Weighted Imaging: Dual Markers of Infarct Progression Stroke. 32: 352-352. DOI: 10.1161/01.Str.32.Suppl_1.352-C |
0.314 |
|
| Show low-probability matches. |